Enterprise Financial Services Corp Has $293,000 Holdings in Novartis AG (NYSE:NVS)

Enterprise Financial Services Corp raised its position in Novartis AG (NYSE:NVS) by 5.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,016 shares of the company’s stock after acquiring an additional 160 shares during the period. Enterprise Financial Services Corp’s holdings in Novartis were worth $293,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Foundations Investment Advisors LLC grew its stake in Novartis by 26.9% in the fourth quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock valued at $8,668,000 after acquiring an additional 18,894 shares during the period. CWA Asset Management Group LLC boosted its position in shares of Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after buying an additional 5,164 shares during the last quarter. Quantbot Technologies LP boosted its position in shares of Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock valued at $4,598,000 after buying an additional 22,998 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Novartis during the fourth quarter valued at approximately $239,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Novartis by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock valued at $18,088,000 after buying an additional 18,990 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Up 2.4 %

NVS opened at $115.60 on Friday. The business has a 50 day simple moving average of $104.02 and a two-hundred day simple moving average of $107.95. The firm has a market capitalization of $236.29 billion, a price-to-earnings ratio of 19.66, a PEG ratio of 1.70 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a one year low of $92.35 and a one year high of $120.92.

Novartis (NYSE:NVS) last announced its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Analysts predict that Novartis AG will post 8.45 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Morgan Stanley began coverage on Novartis in a research report on Wednesday, February 12th. They issued an “underweight” rating for the company. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. UBS Group restated a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.